OCUP Ocuphire Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OCUP

Price (delayed)

$3.39

Market cap

$71.22M

P/E Ratio

3.46

Dividend/share

N/A

EPS

$0.98

Enterprise value

$31.24M

Ocuphire is a publicly traded, clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline currently includes two small- molecule product ...

Highlights
The company's EPS has surged by 195% YoY
The company's net income has surged by 185% YoY
Ocuphire Pharma's equity has surged by 158% YoY but it has decreased by 9% QoQ
The quick ratio has grown by 34% YoY but it has contracted by 31% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ocuphire.com
Peers: OGN

Key stats

What are the main financial stats of OCUP
Market
Shares outstanding
21.01M
Market cap
$71.22M
Enterprise value
$31.24M
Valuations
Price to earnings (P/E)
3.46
Price to book (P/B)
1.88
Price to sales (P/S)
1.57
EV/EBIT
1.65
EV/EBITDA
1.65
EV/Sales
0.69
Earnings
Revenue
$45.27M
EBIT
$18.97M
EBITDA
$18.98M
Free cash flow
$21.64M
Per share
EPS
$0.98
Free cash flow per share
$1.03
Book value per share
$1.8
Revenue per share
$2.16
TBVPS
$2.07
Balance sheet
Total assets
$43.47M
Total liabilities
$5.76M
Debt
$0
Equity
$37.7M
Working capital
$37.7M
Liquidity
Debt to equity
0
Current ratio
7.54
Quick ratio
6.97
Net debt/EBITDA
-2.11
Margins
EBITDA margin
41.9%
Gross margin
100%
Net margin
41.2%
Operating margin
40.1%
Efficiency
Return on assets
49%
Return on equity
54.4%
Return on invested capital
4,696.3%
Return on capital employed
50.3%
Return on sales
41.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OCUP stock price

How has the Ocuphire Pharma stock price performed over time
Intraday
-2.59%
1 week
-12.4%
1 month
-14.39%
1 year
69.5%
YTD
-3.97%
QTD
-21.89%

Financial performance

How have Ocuphire Pharma's revenue and profit performed over time
Revenue
$45.27M
Gross profit
$45.27M
Operating income
$18.15M
Net income
$18.66M
Gross margin
100%
Net margin
41.2%
The company's net income has surged by 185% YoY
The operating income has soared by 183% YoY but it has contracted by 2.4% from the previous quarter
Ocuphire Pharma's net margin has surged by 101% YoY but it has decreased by 8% QoQ
The operating margin has surged by 101% year-on-year but it has declined by 10% since the previous quarter

Growth

What is Ocuphire Pharma's growth rate over time

Valuation

What is Ocuphire Pharma stock price valuation
P/E
3.46
P/B
1.88
P/S
1.57
EV/EBIT
1.65
EV/EBITDA
1.65
EV/Sales
0.69
The company's EPS has surged by 195% YoY
Ocuphire Pharma's equity has surged by 158% YoY but it has decreased by 9% QoQ
The P/B is 33% below the 5-year quarterly average of 2.9 and 16% below the last 4 quarters average of 2.3
The revenue is up by 9% since the previous quarter

Efficiency

How efficient is Ocuphire Pharma business performance
OCUP's ROA has soared by 149% YoY but it is down by 17% from the previous quarter
Ocuphire Pharma's return on equity has surged by 146% YoY but it has decreased by 17% QoQ
The company's return on sales has surged by 101% YoY but it fell by 8% QoQ
The ROIC fell by 10% QoQ

Dividends

What is OCUP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OCUP.

Financial health

How did Ocuphire Pharma financials performed over time
Ocuphire Pharma's total assets has surged by 143% YoY but it has decreased by 4.3% QoQ
The total liabilities has surged by 74% year-on-year and by 39% since the previous quarter
Ocuphire Pharma's debt is 100% lower than its equity
Ocuphire Pharma's equity has surged by 158% YoY but it has decreased by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.